Anti-IL-21: Development discontinued

Novo Nordisk disclosed in its 2013 earnings that it discontinued development of NN8828 for RA based on Phase IIa data. NN8828 is in Phase IIa testing to treat Crohn's disease (CD) and Phase I testing ...